Brickley Wealth Management Has $201,000 Holdings in Johnson & Johnson (NYSE:JNJ)

Brickley Wealth Management cut its position in Johnson & Johnson (NYSE:JNJGet Rating) by 38.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,233 shares of the company’s stock after selling 774 shares during the quarter. Brickley Wealth Management’s holdings in Johnson & Johnson were worth $201,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of JNJ. DORCHESTER WEALTH MANAGEMENT Co boosted its holdings in Johnson & Johnson by 8.6% in the 1st quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 67,618 shares of the company’s stock valued at $14,975,000 after purchasing an additional 5,327 shares during the period. Cantor Fitzgerald Investment Advisor L.P lifted its holdings in shares of Johnson & Johnson by 88.9% during the 1st quarter. Cantor Fitzgerald Investment Advisor L.P now owns 175,194 shares of the company’s stock worth $31,049,000 after acquiring an additional 82,429 shares during the period. AMI Investment Management Inc. lifted its holdings in shares of Johnson & Johnson by 8.8% during the 1st quarter. AMI Investment Management Inc. now owns 18,305 shares of the company’s stock worth $3,244,000 after acquiring an additional 1,475 shares during the period. Equitable Holdings Inc. lifted its holdings in shares of Johnson & Johnson by 4.9% during the 1st quarter. Equitable Holdings Inc. now owns 45,673 shares of the company’s stock worth $8,095,000 after acquiring an additional 2,119 shares during the period. Finally, USS Investment Management Ltd lifted its holdings in shares of Johnson & Johnson by 2.4% during the 1st quarter. USS Investment Management Ltd now owns 860,371 shares of the company’s stock worth $152,488,000 after acquiring an additional 20,528 shares during the period. 67.94% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Stock Down 0.3 %

Shares of NYSE:JNJ opened at $168.31 on Tuesday. Johnson & Johnson has a one year low of $155.72 and a one year high of $186.69. The company has a 50 day moving average of $176.07 and a 200-day moving average of $171.13. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.43 and a quick ratio of 1.18. The stock has a market cap of $440.04 billion, a price-to-earnings ratio of 23.44, a P/E/G ratio of 3.21 and a beta of 0.56.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 7th. Stockholders of record on Tuesday, February 21st will be given a dividend of $1.13 per share. This represents a $4.52 annualized dividend and a dividend yield of 2.69%. The ex-dividend date of this dividend is Friday, February 17th. Johnson & Johnson’s dividend payout ratio is 62.95%.

Insider Transactions at Johnson & Johnson

In other news, EVP Ashley Mcevoy sold 73,323 shares of Johnson & Johnson stock in a transaction that occurred on Wednesday, November 30th. The shares were sold at an average price of $175.47, for a total transaction of $12,865,986.81. Following the completion of the sale, the executive vice president now owns 41,813 shares in the company, valued at approximately $7,336,927.11. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In related news, EVP Ashley Mcevoy sold 73,323 shares of Johnson & Johnson stock in a transaction that occurred on Wednesday, November 30th. The shares were sold at an average price of $175.47, for a total transaction of $12,865,986.81. Following the transaction, the executive vice president now owns 41,813 shares of the company’s stock, valued at approximately $7,336,927.11. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Thibaut Mongon sold 35,246 shares of Johnson & Johnson stock in a transaction that occurred on Friday, November 4th. The stock was sold at an average price of $171.18, for a total transaction of $6,033,410.28. Following the transaction, the vice president now directly owns 40,133 shares in the company, valued at approximately $6,869,966.94. The disclosure for this sale can be found here. Insiders sold a total of 233,611 shares of company stock worth $40,960,735 in the last quarter. 0.35% of the stock is owned by company insiders.

Analyst Ratings Changes

JNJ has been the subject of a number of analyst reports. Credit Suisse Group initiated coverage on shares of Johnson & Johnson in a report on Thursday, November 17th. They set a “neutral” rating and a $170.00 price objective for the company. Morgan Stanley dropped their target price on shares of Johnson & Johnson from $178.00 to $176.00 and set an “equal weight” rating for the company in a research report on Tuesday, December 6th. Barclays assumed coverage on shares of Johnson & Johnson in a research report on Monday, October 17th. They set an “equal weight” rating and a $175.00 target price for the company. Sanford C. Bernstein dropped their target price on shares of Johnson & Johnson from $194.00 to $190.00 in a research report on Wednesday, October 19th. Finally, StockNews.com assumed coverage on shares of Johnson & Johnson in a research report on Wednesday, October 12th. They set a “strong-buy” rating for the company. Seven investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $181.75.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Further Reading

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.